Alpha-1 Antitrypsin (AAT) Deficiency Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Alpha-1 antitrypsin deficiency is an inherited disorder that may cause lung disease and liver disease. The sign and symptoms of people with alpha-1 antitrypsin deficiency usually develop as lung disease between the age of 20 and 50 years. The earliest symptoms of Alpha-1 antitrypsin deficiency include shortness of breath following mild activity, reduced ability to exercise, and wheezing. Other signs and symptoms can include unintentional weight loss, fatigue, recurring respiratory infections, and rapid heartbeat upon standing. Alpha-1 antitrypsin deficiency (A1AD) occurs most frequently in Americans of Northern or Central European descent, affecting approximately 100,000 Americans. The drug candidates of Alpha-1 antitrypsin deficiency pipeline include, but are not limited to, ADVM-043, ARO-AAT and inhaled AAT.

Some of the companies having a drug pipeline for Alpha-1 antitrypsin deficiency include Kamada Ltd., Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies and ProMetic Life Sciences Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.